Agios Pharmaceuticals Inc (AGIO)
22.73
-0.53 (-2.28%)
USD |
NASDAQ |
Mar 20, 16:00
22.74
+0.01 (+0.04%)
After-Hours: 20:00
Agios Pharmaceuticals Free Cash Flow (Quarterly): -66.28M for Dec. 31, 2022
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2022 | -66.28M |
September 30, 2022 | -71.39M |
June 30, 2022 | -76.16M |
March 31, 2022 | -100.54M |
December 31, 2021 | -88.60M |
September 30, 2021 | -85.16M |
June 30, 2021 | -117.54M |
March 31, 2021 | -121.76M |
December 31, 2020 | -49.96M |
September 30, 2020 | -73.41M |
June 30, 2020 | -71.94M |
March 31, 2020 | -109.55M |
December 31, 2019 | -100.29M |
September 30, 2019 | -87.63M |
June 30, 2019 | -89.42M |
March 31, 2019 | -105.31M |
December 31, 2018 | -75.24M |
September 30, 2018 | -66.98M |
June 30, 2018 | -68.76M |
March 31, 2018 | -100.43M |
December 31, 2017 | -75.73M |
September 30, 2017 | -79.73M |
Date | Value |
---|---|
June 30, 2017 | -60.02M |
March 31, 2017 | -74.37M |
December 31, 2016 | -52.44M |
September 30, 2016 | -52.46M |
June 30, 2016 | 155.09M |
March 31, 2016 | -21.54M |
December 31, 2015 | -32.72M |
September 30, 2015 | -28.11M |
June 30, 2015 | -6.902M |
March 31, 2015 | -29.38M |
December 31, 2014 | -9.264M |
September 30, 2014 | -24.10M |
June 30, 2014 | -1.157M |
March 31, 2014 | -27.05M |
December 31, 2013 | -13.84M |
September 30, 2013 | -15.08M |
June 30, 2013 | -16.52M |
March 31, 2013 | -12.26M |
December 31, 2012 | -11.66M |
September 30, 2012 | -12.54M |
June 30, 2012 | -10.83M |
March 31, 2012 | -16.00M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-121.76M
Minimum
Mar 2021
-49.96M
Maximum
Dec 2020
-86.32M
Average
-86.39M
Median
Free Cash Flow (Quarterly) Benchmarks
Moderna Inc | 1.57B |
Alnylam Pharmaceuticals Inc | -153.61M |
Cassava Sciences Inc | -20.98M |
Regeneron Pharmaceuticals Inc | 1.468B |
Karyopharm Therapeutics Inc | -26.84M |